Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning
Viruses · 2025
DOI: 10.3390/v17070935 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2025. Verfasst von Anacleto Silva de Souza und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, Sao Paulo 05508-000, Brazil. Hauptthemen laut MEDLINE: SARS-CoV-2, Machine Learning, Coronavirus 3C Proteases, Antiviral Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: São Paulo Research Foundation (FAPESP), FINEP/UFMG/PRPQ/CT VACINAS/SARS-CoV-2, Coordination for the Improvement of Higher Education Personnel (CAPES).
Abstract (Originalsprache)
The SARS-CoV-2 main protease (Mpro) is a validated therapeutic target for inhibiting viral replication. Few compounds have advanced clinically, underscoring the difficulty in optimizing both target affinity and drug-like properties. To address this challenge, we integrated machine learning (ML), molecular docking, and molecular dynamics (MD) simulations to investigate the balance between pharmacodynamic (PD) and pharmacokinetic (PK) properties in Mpro inhibitor design. We developed ML models to classify Mpro inhibitors based on experimental IC50 data, combining molecular descriptors with structural insights from MD simulations. Our Support Vector Machine (SVM) model achieved strong performance (training accuracy = 0.84, ROC AUC = 0.91; test accuracy = 0.79, ROC AUC = 0.86), while our Logistic Regression model (training accuracy = 0.78, ROC AUC = 0.85; test accuracy = 0.76, ROC AUC = 0.83). Notably, PK descriptors often exhibited opposing trends to binding affinity: hydrophilic features enhanced binding affinity but compromised PK properties, whereas hydrogen bonding, hydrophobic, and π–π interactions in Mpro subsites S2 and S3/S4 are fundamental for binding affinity. Our findings highlight the need for a balanced approach in Mpro inhibitor design, strategically targeting these subsites may balance PD and PK properties. For the first time, we demonstrate antagonistic trends between pharmacokinetic (PK) and pharmacodynamic (PD) features through the integrated application of ML/MD. This study provides a computational framework for rational Mpro inhibitors, combining ML and MD to investigate the complex interplay between enzyme inhibition and drug likeness. These insights may guide the hit-to-lead optimization of the novel next-generation Mpro inhibitors of SARS-CoV-2 with preclinical and clinical potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, Sao Paulo 05508-000, Brazil.
ORCID-Profile: Anacleto Silva de Souza, Eduardo Pereira Soares, Robson Francisco de Souza, Cristiane Rodrigues Guzzo
Förderung
- São Paulo Research Foundation (FAPESP)
- FINEP/UFMG/PRPQ/CT VACINAS/SARS-CoV-2
- Coordination for the Improvement of Higher Education Personnel (CAPES)
- National Council for Scientific and Technological Development (CNPq)
- FINEP
- FAPESP
Zitieren
APA
Souza, A. S., Amorim, V. M. F., Soares, E. P., de Souza, R. F., & Guzzo, C. R. (2025). Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning. Viruses. https://doi.org/10.3390/v17070935
Vancouver
Souza AS, Amorim VMF, Soares EP, de Souza RF, Guzzo CR. Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning. Viruses. 2025. doi:10.3390/v17070935
BibTeX
@article{Souza2025,
author = {Souza, Anacleto Silva de and Amorim, Vitor Martins de Freitas and Soares, Eduardo Pereira and de Souza, Robson Francisco and Guzzo, Cristiane Rodrigues},
title = {Antagonistic Trends Between Binding Affinity and Drug-Likeness in SARS-CoV-2 Mpro Inhibitors Revealed by Machine Learning},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17070935}
}
EUVIMED